Sugi Predict

Sugi Predict / Compounds / SCHEMBL10044644

SCHEMBL10044644

SCHEMBL10044644

CC(C)(Nc1nc(-c2ccc3c(c2)OCO3)ncc1F)C(=O)NCC(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT7 Q9NVM4 2/20 0.46
▸ FGFR3 P22607 6/20 0.41
▸ KDR P35968 4/20 0.41
▸ CLK4 Q9HAZ1 6/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ DYRK1A Q13627 4/20 0.39
▸ ADORA3 P0DMS8 4/20 0.39
▸ ADORA1 P30542 3/20 0.39
▸ ADORA2A P29274 2/20 0.39
▸ ADORA2B P29275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10044773 0.94 PRMT7 (0.46) PRMT7FGFR3KDRCCND1CDK6
SCHEMBL10044684 0.84 CLK4 (0.51) CLK4CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL10044772 0.82 FGFR3 (0.42) FGFR3KDR
SCHEMBL10044780 0.82 FGFR3 (0.42) FGFR3KDR
SCHEMBL10044686 0.81 PRMT7 (0.46) PRMT7FGFR3CLK4CYP1A2CYP3A4
SCHEMBL10044732 0.80 ULK1 (0.42) FGFR3KDRMEN1KMT2AMAPT
SCHEMBL10044648 0.80 FGFR3 (0.43) FGFR3KDRALOX15
SCHEMBL10044647 0.79 GABRA5 (0.41) FGFR3KDR
SCHEMBL10044790 0.79 FGFR3 (0.41) FGFR3KDRNPC1RAB9A
SCHEMBL10044689 0.78 FGFR3 (0.39) FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221336-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 — — US disclosed
US-20140221336-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 — — US disclosed
US-20120157429-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-21 — — US disclosed
US-20120157429-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-21 — — US disclosed
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 — — US disclosed
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157429-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES JAK2, JAK1, JAK3 PRMT7 1103/4885FGFR3 574/4885KDR 997/4885
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES JAK2, JAK1, JAK3 PRMT7 1103/4885FGFR3 574/4885KDR 997/4885
US-20140221336-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES JAK2, JAK1, JAK3 PRMT7 1103/4885FGFR3 574/4885KDR 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.